Screening for Non-Alcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the U.S. is Cost Effective: A Comprehensive Cost-Utility Analysis

Posted on August 4, 2020 by Gastroenterology Journal
This entry was posted in News. Bookmark the permalink.